Brain­storm backs off a con­tro­ver­sial plan to sell its ex­per­i­men­tal ALS med, but this is­sue is far from over

Brain­storm Cell Ther­a­peu­tics $BCLI won’t be an­gling to make any prof­its off the new ‘Right to Try’ bill af­ter all.

Af­ter stir­ring or hor­net’s nest of an­gry Twit­ter memes af­ter Bloomberg quot­ed CEO Chaim Lebovits say­ing that they were prepar­ing to sell their drug to des­per­ate ALS pa­tients, in­clud­ing one who lent his name to the leg­is­la­tion, the mi­cro-cap biotech this morn­ing is back­ing off the idea.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN